![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SIRPB2 |
Gene summary for SIRPB2 |
![]() |
Gene information | Species | Human | Gene symbol | SIRPB2 | Gene ID | 284759 |
Gene name | signal regulatory protein beta 2 | |
Gene Alias | PTPN1L | |
Cytomap | 20p13 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | B3KTG0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284759 | SIRPB2 | HCC1 | Human | Liver | HCC | 1.98e-10 | 1.14e+00 | 0.5336 |
284759 | SIRPB2 | HCC2 | Human | Liver | HCC | 8.10e-08 | 8.34e-01 | 0.5341 |
284759 | SIRPB2 | HCC5 | Human | Liver | HCC | 4.61e-10 | 8.65e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SIRPB2 | SNV | Missense_Mutation | c.310N>A | p.Glu104Lys | p.E104K | Q5JXA9 | protein_coding | tolerated(0.25) | possibly_damaging(0.753) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SIRPB2 | SNV | Missense_Mutation | novel | c.297N>G | p.Ile99Met | p.I99M | Q5JXA9 | protein_coding | deleterious(0.05) | possibly_damaging(0.69) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SIRPB2 | SNV | Missense_Mutation | novel | c.935N>A | p.Ala312Asp | p.A312D | Q5JXA9 | protein_coding | deleterious(0) | possibly_damaging(0.521) | TCGA-E9-A3Q9-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphane | CR |
SIRPB2 | insertion | Frame_Shift_Ins | novel | c.375_376insAAAATTAGTCAGGCGTGGTGGTGCATGCCTGTAATCC | p.His126LysfsTer18 | p.H126Kfs*18 | Q5JXA9 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
SIRPB2 | SNV | Missense_Mutation | novel | c.212N>C | p.Ile71Thr | p.I71T | Q5JXA9 | protein_coding | tolerated(0.08) | possibly_damaging(0.836) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
SIRPB2 | SNV | Missense_Mutation | novel | c.38N>G | p.His13Arg | p.H13R | Q5JXA9 | protein_coding | tolerated(0.1) | benign(0) | TCGA-AA-3971-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | CR |
SIRPB2 | SNV | Missense_Mutation | rs374055663 | c.422C>T | p.Ser141Leu | p.S141L | Q5JXA9 | protein_coding | tolerated(0.66) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SIRPB2 | SNV | Missense_Mutation | c.200N>T | p.Thr67Ile | p.T67I | Q5JXA9 | protein_coding | tolerated(0.57) | benign(0) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
SIRPB2 | SNV | Missense_Mutation | novel | c.631N>C | p.Ser211Pro | p.S211P | Q5JXA9 | protein_coding | tolerated(0.23) | probably_damaging(0.999) | TCGA-AU-3779-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SIRPB2 | SNV | Missense_Mutation | c.839C>A | p.Ala280Glu | p.A280E | Q5JXA9 | protein_coding | tolerated(0.55) | benign(0.055) | TCGA-F4-6460-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |